scholarly journals About hydrastinin

2020 ◽  
Vol 6 (3) ◽  
pp. 300-302
Author(s):  
A. Brandt
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Gelatin Capsules ◽  
Gastrointestinal Canal

At the suggestion of prof. Lhlein's author experimented at the Giessen clinic with Hydrastininum muriaticum. This drug was offered to patients or by mouth in the form of gelatin capsules, the size of a decent pill, containing 0.025 Hydrast. muriat., or under the skin in the form of a sterilized solution containing 0.025-0.1 of this agent. When applying this agent inside or under the skin, the author did not observe any side effects. The functions of the gastrointestinal canal were not disturbed, there were no abscesses at the injection site.

scholarly journals Pfizer-BioNTech vaccine side effects among healthcare workers in Malta

2021 ◽  
Vol 31 (Supplement_3) ◽  
Author(s):  
S Cuschieri ◽  
M Borg ◽  
S Agius ◽  
J Souness ◽  
A Brincat ◽  
...  
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Healthcare Workers ◽  
Response Rate ◽  
Demographic Data ◽  
Regression Analyses ◽  
Eligible Population ◽  
Serious Infection ◽  
E Mail ◽  
Roll Out

Abstract Background COVID-19 vaccination is critical to protect healthcare workers (HCWs) from serious infection. The first vaccine approved for emergency use was the Pfizer-BioNtech vaccine. European countries received their first supplies at the end of December 2020. The European country of Malta started its vaccination roll-out immediately targeting HCWs. The aim of this study was to evaluate side effects. Methods An anonymous online Google Forms survey was disseminated to all HCWs via work e-mail addresses (29th March to 9th April 2021). This gathered demographic data and side-effects regarding pain, redness, and swelling at the injection site, fever, chills, fatigue, muscle/joint pains, headache, vomiting, and diarrhea severity following each dose (Likert scale). Descriptive, comparative, and multiple binary regression analyses were performed. Results There were 1480 responses (response rate 30.30%). The commonest side-effect (SE) was pain at the injection site (88.92% CI95%:87.21-90.42), with the majority reporting it as mild (51%) and moderate (43%). Fatigue reported by 72.97% (CI95%:70.65-75.17), with 42% reporting it as mild and 41% as moderate. Headaches reported by 44.28% (CI95%:41.74-46.80), with 51% claiming to be mild and 34% as moderate. Females had significantly (p = <0.01 respectively) more pain (OR:1.90), redness (OR:2.49), swelling at the injection site (OR:1.33), fever (OR:1.74), chills (OR:2.32), fatigue (OR:2.43), muscle (OR:1.54) and joint pains (OR:2.01), headache (OR:2.07) and vomiting (OR:3.43) when adjusted for age and HCW role. Younger individuals (18-34 years) reported higher SE rates than older adults. Localised SE was reported following both vaccine doses, unlike systemic SE that was mostly reported following second doses. Conclusions Females and young adults appeared to be more susceptible to SE among this study's cohort, however the nature of these SE was mostly mild or moderate. This is encouraging and should allay vaccine apprehension/hesitancy. Key messages Vaccination benefits outweigh the minor side effects experienced. Caring physicians should be notified of the female higher susceptibility to side effects. Vaccination should be encouraged among all eligible population.

scholarly journals Study of the efficacy and safety of proligestone administration for the control of the ovarian cycle in the bitch

2018 ◽  
Vol 49 (1) ◽  
pp. 44
Author(s):  
K. TSELKAS (Κ. ΤΣΕΛΚΑΣ) ◽  
P. YPSILANTIS (Π. ΥΨΗΛΑΝΤΗΣ) ◽  
Ph. SARATSIS (Φ. ΣΑΡΑΤΣΗΣ)
Keyword(s):  
Diabetes Mellitus ◽  
Weight Gain ◽  
Side Effects ◽  
Injection Site ◽  
Ovarian Cycle ◽  
Efficacy And Safety ◽  
Group A ◽  
Group B

In this study the efficacy and safety of the administration of the progestagen proligestone for the control of the ovarian cycle of 66 female dogs were evaluated. Two to six injections of proligestone were made to those animals in anoestrus (group A, n=52) or 1 injection to those in the first 3 days of proestrus (group B, n = 14) in order to prevent or postpone oestrus, respectively. The efficacy of proligestone administration, based on the percentage of successful injections, was 98.07%, 98.03%, 98.00%, 97.67% and 88.00% after the 1st, 2nd, 3rd, 4th and 5th injection, respectively, and 96,83% in total, for group A, while 92.86% for group B. The observed side effects were: hair discoloration at the injection site, weight gain, pyometra and diabetes mellitus at α rate of 11.54%, 7.69%, 1.92% and 1.92%, respectively, for group A and 14.28%,14.28%, 7.14% and 0%, respectively, for group B.

scholarly journals Pattern of adverse events following immunization among recipients of first dose of ChAdOx1-S [recombinant] Covid-19 vaccine in a resource-limited country

2021 ◽  
Vol 12 (1) ◽  
pp. 006-012
Author(s):  
Azubuike Benjamin Nwako ◽  
Okechukwu Francis Nwako ◽  
Charles Emeka Nwolisa ◽  
Magaret-Lorritta Chidimma Nwako ◽  
Charles Nwaora Nwako
Keyword(s):  
Side Effects ◽  
Adverse Events ◽  
Injection Site ◽  
Health Workers ◽  
Health Information System ◽  
Secondary Data ◽  
Allergic Reactions ◽  
District Health ◽  
Cross Sectional ◽  
Resource Limited

Background/Aim: Vaccines are said to be associated with side effects. The aim of the study was to show the pattern and distribution of adverse events following immunization observed with ChAdOx1-S [recombinant] Covid-19 vaccine after the first dose. Methodology: The study design was cross-sectional descriptive study over four weeks. We included records of 6589 high risk recipients of the vaccine and 33 of them who reported adverse events following immunization. The study used secondary data from the covid-19 vaccination register and District Health Information system II. Result: Out of 6589 individuals vaccinated with the first dose of ChAdOx1-S [recombinant] Covid-19 vaccine, 69.66% were female, 69.49% were fifty-five years or less, 86.04% were health workers and 27.26% had comorbidity. Only 0.5% of those vaccinated reported adverse events following immunization out of which 0.41% was systemic, 0.06% local and 0.03% allergic reactions. The commonest systemic side effects were headache and dizziness while local adverse events had pain at injection site as the commonest side effect. Multiple swelling in the buttock and swelling of the face and lip were the only two cases of allergic reactions reported. Eighty-eight percent of those who reported side effects did so on the day of vaccination. Conclusion The study reported less adverse events with the first dose of ChAdOx1-S [recombinant] Covid-19 vaccine than in other studies which included headache, dizziness and pain at the injection site. Most were reported in the first day of vaccination. There is need for encouraging vaccine recipients to report any adverse events following immunization.

COVID-19 Vaccine and Fitness to Fly

2021 ◽  
Vol 92 (9) ◽  
pp. 698-701
Author(s):  
Daniel Gabbai ◽  
Aya Ekshtein ◽  
Omer Tehori ◽  
Oded Ben-Ari ◽  
Shachar Shapira
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Air Force ◽  
Side Effect ◽  
Common Side Effect ◽  
Injection Site Pain ◽  
Dose Administration ◽  
The Difference ◽  
Site Pain ◽  
The U.S

INTRODUCTION: On December 2020 the U.S. Food and Drug Administration (FDA) authorized the emergency use of Pfizer-BioNTech COVID-19 vaccine. This new vaccine has several side effects that can potentially impair function, which warrants special attention regarding aircrews fitness to fly following vaccination.METHODS: A survey was conducted in the Israeli Air Force (IAF) Aeromedical Center in order to characterize the side effects and their duration following Pfizer-BioNTech COVID-19 vaccine administration to aviators.RESULTS: The most common side effect was injection site pain. Headache, chills, myalgia, fatigue, and weakness were more common following the second dose administration. The difference is statistically significant. Following the second vaccine, duration of side effects was longer compared to the first vaccine (P-value 0.002).CONCLUSION: The IAF Aeromedical center policy for Pfizer-BioNTech COVID-19 vaccine recipients among aircrew members, based on side effects duration and severity, is to temporarily ground from flight duties for 24 and 48 h following the first and the second dose, respectively.Gabbai D, Ekshtein A, Tehori O, Ben-Ari O, Shapira S. COVID-19 vaccine and fitness to fly. Aerosp Med Hum Perform. 2021; 92(9):698701.

Aseptic myonecrosis following intramuscular benzathine penicllin G injection: a novel syndrome

Diagnosis ◽  
2017 ◽  
Vol 4 (1) ◽  
pp. 51-54 ◽  
Author(s):  
Nicholas Ryan ◽  
Andrew Olson
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Pediatric Patient ◽  
Similar Case ◽  
Streptococcal Pharyngitis ◽  
Penicillin G ◽  
Injection Site Pain ◽  
Benzathine Penicillin ◽  
Benzathine Penicillin G ◽  
Site Pain

AbstractWe report a novel syndrome of aseptic myonecrosis in a child occurring after intramuscular (IM) benzathine penicillin G injection for the treatment of streptococcal pharyngitis. Common side effects of IM injection, including transient injection site pain and inflammation, are common and well described. However, isolated myonecrosis following IM injection in the pediatric patient has not been previously reported. Only one similar case, following IM diclofenac injection, has been discussed in the adult literature.

scholarly journals Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools

2014 ◽  
Vol 42 (4) ◽  
pp. 492-500 ◽  
Author(s):  
Matt Lamkin ◽  
Carl Elliott
Keyword(s):  
Multiple Sclerosis ◽  
Health Insurance ◽  
Medication Adherence ◽  
Side Effects ◽  
Injection Site ◽  
Health Information ◽  
Pharmaceutical Marketing ◽  
Phone Call ◽  
Patient Medication ◽  
Bee Sting

About a week after Maran Wolston was prescribed Copaxone, a drug for multiple sclerosis (MS), she got a phone call from a nurse at an organization called Shared Solutions. The organization was familiar to Wolston; when her neurologist had asked permission to share her health information with Shared Solutions, Wolston had agreed, assuming it was connected to her health insurance. The nurse who called Wolston was checking in to see how the treatment was going. It was not going well. While Copaxone is not typically associated with some of the unpleasant side effects of other MS drugs, it does have at least one serious drawback: the drug must be injected every day. The injections can be brutally painful. “No matter where I injected the drug each day, the injection site swelled up into a huge welt and felt like a gigantic bee sting,” Wolston writes.

scholarly journals Side Effects after Second Dose of Covishield Vaccine among Health Care Workers: A Descriptive Cross Sectional Study

2021 ◽  
Vol 59 (238) ◽  
Author(s):  
Khilasa Pokharel ◽  
Bishwa Raj Dawadi ◽  
Anup Karki
Keyword(s):  
Health Care ◽  
Side Effects ◽  
Injection Site ◽  
Health Care Workers ◽  
Deltoid Muscle ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Care Workers ◽  
Ethical Approval

ABSTRACT Introduction: COVID 19 vaccination will protect us from getting COVID-19. Some side effects are common which are signs that our body is building protection. This side effects will go away in a few days. The aim of this study is to find out side effects seen among health care workers after second dose of covishield vaccination. Methods: This was a descriptive cross-sectional study conducted at Kathmandu medical college and Teaching Hospital from 22nd April 2021 till 30th April 2021. Ethical approval was revceived from Institutional Commitee of Institiute. Convienient sampling was done. The second dose of covishield vaccine was administered 12 weeks after its first dose. The vaccine was administered intramuscularly (IM) into deltoid muscle. Statistical Package for the Social Sciences were used for analysis. Results: Out of 220 cases taken, 135 were male and 85 were female. In our study 178 (80.90%) complaint of pain at injection site after second dose of covishield vaccine followed by 97 (44.09%) complaint of fatigue, 43 (19.54%) complaint of headache, 18 (8.18%) complaint of chills, 11 (5.00%)complaint of fever, 6 (2.72%) complaint of dizziness and 5 (2.27%) complaint of nausea. Conclusions: Pain at injection site, fatigue and headache were common side effects seen after second dose of Covishield vaccination.

Treatment of Ranula with Intracystic Injection of the Streptococcal Preparation Ok-432

2003 ◽  
Vol 112 (3) ◽  
pp. 214-220 ◽  
Author(s):  
Shigeru Fukase ◽  
Kazutoshi Inamura ◽  
Nobuo Ohta ◽  
Masaru Aoyagi
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Marked Reduction ◽  
Cystic Hygroma ◽  
The Other ◽  
Outpatient Basis ◽  
Local Pain ◽  
First Choice ◽  
Streptococcal Preparation ◽  
Intracystic Injection

Intracystic injection of OK-432 was developed as a therapy for operatively difficult lymphangioma (cystic hygroma) and is currently becoming a treatment of first choice for this disease. We tried this therapy in 32 patients with ranula (oral floor type in 21 cases and plunging type in 11 cases). Disappearance or marked reduction of the lesion was observed in 31 patients (97%) who had this therapy, and local scarring did not occur in any patient. As side effects, local pain at the injection site and fever (37°C to 39°C) were observed in almost half of the patients who had this therapy, but such problems resolved within a few days. We treated the initial 4 cases in the hospital for 4 to 5 days, but after the safety of this method had been confirmed, we treated the other 28 cases on an outpatient basis. Thus, we confirmed that intracystic injection therapy with OK-432 is relatively safe and can be used as a substitute for surgery in the treatment of ranulas.

scholarly journals COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter?

Vaccines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1156
Author(s):  
Mohamed Hassan Elnaem ◽  
Nor Hidayah Mohd Taufek ◽  
Norny Syafinaz Ab Rahman ◽  
Nor Ilyani Mohd Nazar ◽  
Che Suraya Zin ◽  
...  
Keyword(s):  
Side Effects ◽  
Injection Site ◽  
Side Effect ◽  
Lower Risk ◽  
Age Groups ◽  
Vaccine Safety ◽  
Vaccination Program ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Vaccine Type

This study aimed to investigate the attitudes, perceptions, and experiences of side effects with the COVID-19 vaccines in Malaysia among participants in the National Vaccination Program. A cross-sectional survey was conducted among a sample of vaccine-eligible and vaccinated individuals in Malaysia between May and July 2021. A total of 428 respondents completed the survey. A vast majority (98.6%) of the respondents had registered to be vaccinated. Twenty participants (4.7%) expressed concerns about either registering or receiving the COVID-19 vaccination, mainly due to their uncertainty of vaccine safety. Approximately 77.5% received their vaccinations. Of them, 76.8% had experienced vaccine-related side effects. About 40% of the side effects occurred more with the second dose, particularly those who received the Pfizer-BioNTech vaccine (p < 0.001). Pain at the injection site (61.1%) and tiredness (48.8%) were the most reported side effects. Compared to those aged ≥60 years, all age groups were more likely to exhibit vaccine-related side effects; meanwhile, males (OR: 0.51, 95% CI: 0.27–0.93) were less likely to experience side effects than females. Those who received the Sinovac vaccine were at lower risk of experiencing side effects (OR: 0.08, 95% CI: 0.03–0.22) and were more likely to report fewer side effects than Pfizer-BioNTech (p = 0.012) and Oxford-AstraZeneca groups (p= 0.001). The overall attitudes toward the COVID-19 vaccination program were positive. Several differences in the experiences of vaccine-related side effects, in terms of prevalence and numbers, were attributed to age, gender, and received vaccine type.

Sign in / Sign up

Export Citation Format

Share Document